Updated results and biomarker analyses from the phase 2 trial of nab-paclitaxel plus sintilimab as second-line therapy for advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (G/GEJA).

Zhichao Jiang(Chinese Academy of Medical Sciences & Peking Union Medical College), Aiping Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Yongkun Sun(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Deng(Capital Medical University), Lin Yang(Alberta Health Services), Yunbo Zhao(University of Science and Technology of China), Wen Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Liang Cui
Journal of Clinical Oncology
June 1, 2024
10.1200/jco.2024.42.16_suppl.4037
Cited by 1

Related Papers

Bladder cancer cell-derived exosomes inhibit tumor cell apoptosis and induce cell proliferation in vitro
|Molecular Medicine Reports|2013|158
The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients
|Biological Trace Element Research|1997|122
Clinical characteristics, medical service utilization, and expenditure for colorectal cancer in China, 2005 to 2014: Overall design and results from a multicenter retrospective epidemiologic survey
|Cancer|2021|106
First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer
|JAMA|2025|72
Anlotinib Monotherapy for Refractory Metastatic Colorectal Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Trial (ALTER0703)
|The Oncologist|2021|64